A significant contributor to NSCLC oncogenesis is the mesenchymal lymphoma kinase (anaplastic lymphoma receptor tyrosine kinase [ALK]) fusion mutations, often associated with accelerated cancer progression 110. Here, ALK is linked to non-small cell lung carcinoma.